Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Fuji
Colorcon
Express Scripts
Mallinckrodt
Cantor Fitzgerald
Medtronic
McKesson
Boehringer Ingelheim

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,469,030

« Back to Dashboard

Which drugs does patent 6,469,030 protect, and when does it expire?

Patent 6,469,030 protects ENTEREG and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.
Summary for Patent: 6,469,030
Title: Methods for the treatment and prevention of ileus
Abstract:Methods for the treatment and/or prevention of ileus are disclosed. The methods comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates.
Inventor(s): Farrar; John J. (Chester Springs, PA), Schied; Peter J. (Southampton, PA), Schmidt; William K. (Newark, DE), Carpenter; Randall L. (Waban, MA)
Assignee: Adolor Corporation (Exton, PA)
Application Number:09/725,708
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,469,030

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD OF TREATING OR PREVENTING ILEUS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,469,030

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,696,220 Methods for the treatment or inhibition of ileus ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKesson
Cerilliant
Merck
Citi
Boehringer Ingelheim
Farmers Insurance
Express Scripts
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.